Olivopontocerebellar atrophy
Also known as: Atrophy, Atrophic, Atrophies, Wasted
Methodology & AI Transparency ⓘ
Olivopontocerebellar atrophy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Olivopontocerebellar atrophy (also termed Atrophy or Atrophic) (ICD-10-CM G23.8), Neurology, Stroke & Movement Disorders protocols prioritize vascular stroke risk in Olivopontocerebellar atrophy (G23.8: stratification) paired with baseline and interval HbA1c & Blood in Olivopontocerebellar atrophy (G23.8: Pressure Neuro-Targets) assessment.
- 2 Real-world patient consensus: Mapped to Neurology, Stroke & Movement Disorders under ICD-10-CM G23.8 for Olivopontocerebellar atrophy clinical workups.
- 3 Typical cash cost range: Differential triage of Olivopontocerebellar atrophy (G23.8) utilizes vascular stroke risk in Olivopontocerebellar atrophy (G23.8: stratification).
- 4 Top reported side effects / signs: Longitudinal Olivopontocerebellar atrophy monitoring tracks HbA1c & Blood in Olivopontocerebellar atrophy (G23.8: Pressure Neuro-Targets) toward BP < 120/75 mmHg; HbA1c < 5.7% (G23.8).
Ask our AI Specialists anything about Olivopontocerebellar atrophy
What Is Olivopontocerebellar atrophy?
For patients presenting with Olivopontocerebellar atrophy (also termed Atrophy or Atrophic) (ICD-10-CM G23.8), Neurology, Stroke & Movement Disorders protocols prioritize vascular stroke risk in Olivopontocerebellar atrophy (G23.8: stratification) paired with baseline and interval HbA1c & Blood in Olivopontocerebellar atrophy (G23.8: Pressure Neuro-Targets) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
In Olivopontocerebellar atrophy (G23.8), physiological disruption stems from or basal ganglia in Olivopontocerebellar atrophy (G23.8: dopaminergic circuit degeneration), informing Neurology, Stroke & Movement Disorders protocols that track Serum Vitamin B12 in Olivopontocerebellar atrophy (G23.8: & Methylmalonic Acid) (B12 > 500 pg/mL; MMA < 240 nmol/L (G23.8)).
Common Symptoms & Clinical Signs
- • Presentation of Olivopontocerebellar atrophy (G23.8): numbness, paresthesia, or in Olivopontocerebellar atrophy (G23.8: visual field/speech changes)
- • Secondary Olivopontocerebellar atrophy clinical sign: muscle stiffness, spasticity, in Olivopontocerebellar atrophy (G23.8: or fatigable neuromuscular)
- • Symptom flares in Olivopontocerebellar atrophy correlating with HbA1c & Blood in Olivopontocerebellar atrophy (G23.8: Pressure Neuro-Targets) deviation outside BP < 120/75 mmHg; HbA1c < 5.7% (G23.8)
- • Functional brain & neurology impact requiring vascular stroke risk in Olivopontocerebellar atrophy (G23.8: stratification) evaluation (G23.8)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Olivopontocerebellar atrophy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G23.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neurology, Stroke & Movement Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: HbA1c & Blood in Olivopontocerebellar atrophy (G23.8: Pressure Neuro-Targets) | BP < 120/75 mmHg; HbA1c < 5.7% (G23.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Olivopontocerebellar atrophy (G23.8: & Methylmalonic Acid) | B12 > 500 pg/mL; MMA < 240 nmol/L (G23.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Carotid Duplex / in Olivopontocerebellar atrophy (G23.8: Cerebral Perfusion) | No hemodynamically significant stenosis (G23.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Olivopontocerebellar atrophy
Treatment selection for Olivopontocerebellar atrophy depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Olivopontocerebellar atrophy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple These data suggest that plasma GFAP is a relapse-independent metric of baseline disease severity and a predictor of treatment response in participants with RMS. European journal of neurology • 2025-06-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40462564 ↗ |
Olivopontocerebellar atrophy Patient Community & “People Like Me” Threads
Filter Olivopontocerebellar atrophy community threads and patient logs by age, biological sex, dosage, and treatment duration.